An experimental compound promoted online for pain relief, healing, and athletic performance enhancement is being consumed for a wide variety of medical conditions despite a lack of rigorous scientific evidence regarding its safety and effectiveness, according to a new analysis.
The compound—known as BPC-157—has been backed by U.S. Health Secretary Robert F. Kennedy Jr.
Although it lacks approval in the United States, the substance has developed a substantial consumer base within a gray market. Driven by social media posts promoting unverified claims about muscle growth and injury recovery, it is frequently combined with a second peptide, TB-500, in a pairing popularly called the “Wolverine stack.”
In July, an advisory panel for the U.S. Food and Drug Administration voted to permit pharmacy compounding of BPC-157, a step advocated by Kennedy.
The FDA has not yet announced a final determination on whether compounding will be authorized. The agency previously restricted BPC-157 compounding, citing significant safety concerns and a lack of sufficient human trial data.
Market analysts estimate that BPC-157 and similar peptides could rapidly expand into a $2 billion to $3 billion industry if granted regulatory legitimacy.
Monitoring actual usage of BPC-157 is challenging because the product lacks a designated National Drug Code. To measure its clinical footprint, data analytics firm nference searched more than 15 million medical files and identified 1,039 patients whose physicians had manually recorded use of the peptide in written clinical notes.
Venky Soundararajan, who led the study, emphasized that the findings offer only a partial view because the full scope of consumption remains unmeasured.
“Most likely, very few doctors are even asking their patients, ‘Are you taking BPC-157?’” he said.
Researchers found that the number of confirmed new users grew 33-fold between 2020 and 2026.
Documented reasons for taking the unapproved substance were available for 644 patients, who used it for ailments spanning chronic pain, sports injuries, and gastrointestinal disorders.
Patients most frequently initiated BPC-157 to manage gastrointestinal issues or pain, acquiring the compound primarily from gray-market suppliers or compounding pharmacies.
The demographic makeup of users shifted over time: the proportion of male users grew from 57% in 2020 to 70% in 2026, while the average age fell from 55 to 49. Among 972 users with recorded race data, 96% were white.
Treatment outcomes were recorded for only one-third of the study participants. While some medical entries cited symptom improvements, the limited records highlighted ongoing uncertainty regarding the peptide’s overall performance, safety, and efficacy, according to the report published prior to peer review.
When individuals stopped taking BPC-157, it was usually because their doctor recommended stopping. Others reported side effects, including gastrointestinal, dermatologic, and neuropsychiatric symptoms.
Data from the FDA’s Adverse Event Monitoring System shows 10 reports of serious adverse events involving BPC-157 since 2021, with eight of those reported in 2026.
The FDA notes that a submission to the system, formerly known as FAERS, does not confirm causation, as reports submitted by patients, physicians, or businesses are not independently verified by the agency.
Dr. Flynn McGuire of the University of Utah, a researcher familiar with BPC-157 who was not involved in the analysis, pointed out that roughly half the patients identified by nference were simultaneously taking other medications—including corticosteroids, testosterone, NSAIDs, and TB-500—or undergoing therapies such as physical rehabilitation and surgery.
“There was no placebo or untreated comparator, and there was no standardized indication, formulation, dose, route, treatment duration, or outcome assessment,” he said.
Consequently, McGuire and the study authors noted that it is impossible to determine how much of any reported recovery was caused by BPC-157 rather than natural healing, concurrent therapies, placebo responses, or selective documentation.
The paper “tells us a lot about who is using BPC-157, how they are using it, and what is being reported in practice,” McGuire said. However, he emphasized that randomized controlled trials remain necessary to establish whether BPC-157 provides genuine clinical benefits.
